QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity Digital PCR system, enabling simultaneous analysis of up to 12 targets from a single biological sample, more than doubling its previous capability of five targets. This upgrade is achieved through the new QIAcuity Software 3.1 and the launch of the QIAcuity High Multiplex Probe PCR Kit, requiring no hardware changes to existing instruments.
The system has shown strong market adoption with over 2,700 cumulative placements by end of 2024 and citations in more than 550 publications. The enhancement makes lab work more efficient by reducing time, reagent consumption, and sample material usage. The platform integrates partitioning, thermocycling, and imaging into a streamlined workflow, reducing processing times from six to two hours.
The QIAcuity platform is available in one-, four-, and eight-plate versions to accommodate different laboratory sizes and throughput requirements. The technology is particularly valuable for applications in translational research, microbiome analysis, pathogen detection, and cell and gene therapy development.
QIAGEN (NYSE: QGEN) ha annunciato miglioramenti significativi al suo QIAcuity Digital PCR system, che consente l'analisi simultanea di fino a 12 target da un singolo campione biologico, più del doppio della capacità precedente di cinque target. Questo aggiornamento è stato realizzato attraverso il nuovo QIAcuity Software 3.1 e il lancio del QIAcuity High Multiplex Probe PCR Kit, senza la necessità di modifiche hardware agli strumenti esistenti.
Il sistema ha mostrato una forte adozione sul mercato con oltre 2.700 posizionamenti cumulativi entro la fine del 2024 e citazioni in più di 550 pubblicazioni. Il miglioramento rende il lavoro di laboratorio più efficiente riducendo il tempo, il consumo di reagenti e l'uso di materiale campionamento. La piattaforma integra partizionamento, termociclazione e imaging in un flusso di lavoro semplificato, riducendo i tempi di elaborazione da sei a due ore.
La piattaforma QIAcuity è disponibile in versioni da uno, quattro e otto piastre per soddisfare le diverse dimensioni dei laboratori e i requisiti di throughput. La tecnologia è particolarmente preziosa per applicazioni nella ricerca traslazionale, nell'analisi del microbioma, nella rilevazione di patogeni e nello sviluppo di terapie cellulari e geniche.
QIAGEN (NYSE: QGEN) ha anunciado mejoras significativas en su QIAcuity Digital PCR system, que permite el análisis simultáneo de hasta 12 objetivos a partir de una sola muestra biológica, más del doble de su capacidad anterior de cinco objetivos. Esta actualización se logra a través del nuevo QIAcuity Software 3.1 y el lanzamiento del QIAcuity High Multiplex Probe PCR Kit, sin necesidad de cambios de hardware en los instrumentos existentes.
El sistema ha mostrado una fuerte adopción en el mercado con más de 2,700 ubicaciones acumulativas a finales de 2024 y citas en más de 550 publicaciones. La mejora hace que el trabajo en el laboratorio sea más eficiente al reducir el tiempo, el consumo de reactivos y el uso de material de muestra. La plataforma integra particionamiento, termociclado e imágenes en un flujo de trabajo simplificado, reduciendo los tiempos de procesamiento de seis a dos horas.
La plataforma QIAcuity está disponible en versiones de una, cuatro y ocho placas para adaptarse a diferentes tamaños de laboratorio y requisitos de rendimiento. La tecnología es particularmente valiosa para aplicaciones en investigación traslacional, análisis del microbioma, detección de patógenos y desarrollo de terapias celulares y génicas.
QIAGEN (NYSE: QGEN)은 QIAcuity Digital PCR system의 중요한 개선 사항을 발표하였으며, 이를 통해 단일 생물학적 샘플에서 최대 12개의 타겟을 동시에 분석할 수 있게 되어 이전의 5개 타겟에서 더블 이상의 용량을 충족하게 되었습니다. 이 업그레이드는 새로운 QIAcuity Software 3.1과 QIAcuity High Multiplex Probe PCR Kit의 출시를 통해 이루어지며, 기존 기계에 대한 하드웨어 변경이 필요하지 않습니다.
이 시스템은 2024년 말까지 2,700건 이상의 누적 설치 및 550편 이상의 출처에서 인용되며, 시장에서 강력한 채택을 보였습니다. 이 개선은 시간, 시약 소비 및 샘플 자재 사용을 줄임으로써 실험실 작업을 더 효율적으로 만들어 줍니다. 플랫폼은 파티셔닝, 열 사이클링 및 이미징을 통합하여 간소화된 워크플로우를 제공하며, 처리 시간을 6시간에서 2시간으로 단축합니다.
QIAcuity 플랫폼은 다양한 실험실 크기와 처리 요구에 맞추어 1개, 4개, 8개 플레이트 버전으로 제공됩니다. 이 기술은 번역 연구, 미생물 군집 분석, 병원체 탐지 및 세포 및 유전자 치료 개발 응용에 특히 유용합니다.
QIAGEN (NYSE: QGEN) a annoncé des améliorations significatives à son QIAcuity Digital PCR system, permettant l'analyse simultanée de jusqu'à 12 cibles à partir d'un seul échantillon biologique, ce qui représente plus du double de sa capacité précédente de cinq cibles. Cette mise à niveau est réalisée grâce au nouveau QIAcuity Software 3.1 et au lancement du QIAcuity High Multiplex Probe PCR Kit, sans nécessiter de modifications matérielles des instruments existants.
Le système a montré une forte adoption sur le marché avec plus de 2 700 installations cumulées d'ici la fin 2024 et des citations dans plus de 550 publications. L'amélioration rend le travail de laboratoire plus efficace en réduisant le temps, la consommation de réactifs et l'utilisation de matériel d'échantillon. La plateforme intègre le partitionnement, le thermocyclage et l'imagerie dans un flux de travail rationalisé, réduisant les temps de traitement de six à deux heures.
La plateforme QIAcuity est disponible en versions à une, quatre et huit plaques pour s'adapter à différentes tailles de laboratoire et exigences de débit. La technologie est particulièrement précieuse pour des applications en recherche translationnelle, analyse du microbiome, détection de pathogènes et développement de thérapies cellulaires et géniques.
QIAGEN (NYSE: QGEN) hat bedeutende Verbesserungen seines QIAcuity Digital PCR system angekündigt, das die gleichzeitige Analyse von bis zu 12 Zielen aus einer einzigen biologischen Probe ermöglicht, was mehr als eine Verdopplung der vorherigen Kapazität von fünf Zielen darstellt. Dieses Upgrade wird durch die neue QIAcuity Software 3.1 und die Einführung des QIAcuity High Multiplex Probe PCR Kit erreicht, wobei keine Hardwareänderungen an bestehenden Instrumenten erforderlich sind.
Das System hat eine starke Marktakzeptanz mit über 2.700 kumulierten Platzierungen bis Ende 2024 und Zitierungen in mehr als 550 Publikationen gezeigt. Die Verbesserung macht die Laborarbeit effizienter, indem Zeit, Reagenzienverbrauch und Materialbedarf an Proben reduziert werden. Die Plattform integriert Partionierung, Thermalzyklen und Bildgebung in einen optimierten Arbeitsablauf und verkürzt die Bearbeitungszeiten von sechs auf zwei Stunden.
Die QIAcuity Plattform ist in Versionen mit einem, vier und acht Platten erhältlich, um verschiedenen Laborgrößen und Durchsatzanforderungen gerecht zu werden. Die Technologie ist besonders wertvoll für Anwendungen in der translationalen Forschung, Mikrobiom-Analyse, Pathogenerkennung sowie in der Entwicklung von Zell- und Gentherapien.
- Doubled analysis capability from 5 to 12 targets without hardware changes
- Strong market adoption with 2,700+ system placements
- Cited in over 550 publications
- 67% reduction in processing time (from 6 to 2 hours)
- No additional hardware investment required for upgrade
- None.
Insights
The enhanced multiplexing capabilities of QIAcuity represent a significant technological advancement in digital PCR technology. The ability to analyze 12 targets simultaneously, up from 5, without hardware changes is particularly impressive. This upgrade substantially improves laboratory efficiency by reducing sample consumption, time and reagent costs - critical factors in research economics.
The system's technological sophistication, evidenced by features like crosstalk compensation and optimized master mix for microfluidic applications, positions QIAGEN strongly in the competitive dPCR market. With 2,700 placements and 550+ publications citing the technology, QIAcuity has demonstrated robust market penetration and scientific validation.
For investors, this advancement strengthens QIAGEN's position in the growing digital PCR market, particularly valuable in high-growth areas like cell and gene therapy development, translational research and clinical diagnostics. The software-based upgrade approach also suggests strong margins on this enhancement, as it requires minimal additional hardware costs.
QIAGEN's strategic expansion of QIAcuity's capabilities addresses the growing demand for more efficient and cost-effective molecular analysis solutions. The 140% increase in multiplexing capacity (from 5 to 12 targets) significantly enhances the platform's value proposition, particularly for pharmaceutical companies and research institutions seeking to maximize research budgets.
The existing install base of 2,700 instruments represents a substantial recurring revenue opportunity through the new High Multiplex Probe PCR Kit sales. The software upgrade model demonstrates QIAGEN's ability to enhance product value post-sale, potentially driving both customer retention and incremental revenue growth. The expansion into clinical testing with QIAcuityDx further diversifies the revenue streams and expands the total addressable market.
-
QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets
-
No instrument hardware changes required for upgraded capability thanks to new QIAcuity Software 3.1 update and launch of QIAcuity High Multiplex Probe PCR Kit
- New QIAcuity digital PCR capabilities helps make lab work more productive and cost-efficient through savings on time, reagents consumption and use of precious sample materials
VENLO,
The new capabilities overcome the assay design challenges of currently available quantitative multiplex PCR methods, making QIAcuity digital PCR ideal for applications such as translational research, microbiome analysis, pathogen detection and the development of cell and gene therapies.
Through a software upgrade and the launch of the new QIAcuity High Multiplex Probe PCR Kit, customers can now analyze up to 12 targets simultaneously compared to the earlier version offering up to five targets, using their existing instruments without any hardware changes.
This upgrade provides QIAcuity customers with a powerful technology that amplifies and detects multiple targets within a single reaction. By combining multiple PCR assays, researchers can now maximize sample use while simultaneously reducing time and reagent consumption that accelerates the process to obtain deep biological insights.
“Analyzing more targets simultaneously from a single biological sample is an important step in making QIAcuity even more the top choice for groundbreaking dPCR applications,” said Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN. “We are exploring ways to further increase the capabilities of QIAcuity to help researchers gain a deeper biological understanding of any sample type in a cost-efficient way without tedious optimization or fear of inaccurate quantification.”
The adoption of QIAcuity digital PCR research instrument is strong, with more than 2,700 cumulative placements at the end of 2024 and citations in over 550 publications. Key customers include pharmaceutical and biotechnology companies, academic and research organizations and forensic laboratories. In the fall of 2024, QIAGEN expanded its dPCR portfolio into clinical testing with the launch of QIAcuityDx, which is designed to address clinical customer segments and applications and to further strengthen the QIAcuity family.
The QIAcuity High Multiplex Probe PCR Kit contains a ready-to-use master mix optimized for microfluidic use in the QIAcuity Nanoplates and lets users conveniently perform high-order multiplexing on existing QIAcuity instruments. The kit enhances the specificity and efficiency of probe-based digital PCR to provide accurate singleplex, or up to 12-plex analysis.
As a prerequisite to use the QIAcuity High Multiplex Probe PCR Kit, the QIAcuity Software 3.1 introduces essential features for high-order multiplexing such as crosstalk compensation which corrects signal overlap between targets. This enables researchers to confidently analyze more targets in parallel from one undivided sample.
QIAcuity dPCR catalog and custom assays for copy number variation (CNV) analysis and microbial detection have been re-designed to support up to 12-plex reactions. These assays are available through QIAGEN’s GeneGlobe platform.
The combination of sophisticated software and innovative chemistry make QIAcuity dPCR a superior solution for high-order multiplexing. It enhances workflows by offering greater target capacity and improved data reliability while QIAcuity remains the dPCR system with the highest throughput and is highly automation-friendly.
QIAGEN's QIAcuity digital PCR platform utilizes nanoplates to disperse a sample into thousands of tiny partitions and then reads the reaction in each one simultaneously to quantify even the faintest signals from DNA and RNA. The platform integrates partitioning, thermocycling, and imaging into a streamlined multiplex workflow, reducing processing times from six hours to just two. Available in one-, four-, and eight-plate versions, the platform meets the needs of a wide range of laboratory sizes and throughput requirements.
For more information about QIAcuity’s new multiplexing capabilities, please visit: https://www.qiagen.com/applications/digital-pcr/beginners/dpcr-multiplexing
About QIAGEN
QIAGEN N.V., a
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the
Source: QIAGEN N.V.
Category: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109845369/en/
QIAGEN:
Investor Relations
John Gilardi +49 2103 29 11711
Domenica Martorana +49 2103 29 11244
e-mail: ir@QIAGEN.com
Public Relations
Thomas Theuringer +49 2103 29 11826
Lisa Specht +49 2103 29 14181
e-mail: pr@QIAGEN.com
Source: QIAGEN N.V.
FAQ
What is the new target analysis capability of QGEN's QIAcuity Digital PCR system?
How many QIAcuity systems has QGEN placed in the market as of 2024?
What is the processing time reduction achieved by QGEN's QIAcuity platform?
What are the key applications for QGEN's enhanced QIAcuity Digital PCR system?
How many scientific publications have cited QGEN's QIAcuity system?
